返回 
加入收藏
依奇珠单抗治疗中重度斑块状银屑病的药物经济学评价
x
请在关注微信后，向客服人员索取文件
| 篇名： | 依奇珠单抗治疗中重度斑块状银屑病的药物经济学评价 |
| TITLE： | Pharmacoeconomic Evaluation of Ixekizumab in the Treatment of Moderate-to-severe Plaque Psoriasis |
| 摘要： | 目的：评估依奇珠单抗治疗中重度斑块状银屑病的药物经济性。方法：计算机系统检索PubMed、Embase、TheCochraneLibrary和中国知网、万方数据库等数据库，并辅以手工检索，检索时间为自建库起至2019年10月31日，中英文检索词包括“依奇珠单抗“”拓咨“”银屑病“”药物经济学“”成本-效益分析“”成本-效果分析“”成本-效用分析“”Ixekizumab“”Taltz“”Psoriasis“”Phar-macoeconomics“”Cost-benifitanalysis“”Cost-effectivenessanalysis“”Cost-utilityanalysis”等，根据纳入与排除标准筛选文献，收集依奇珠单抗治疗中重度斑块状银屑病的相关药物经济学研究并对其进行质量评价。对纳入研究的研究方法、药物经济学评价结果等进行归纳、总结。结果：共纳入8篇文献，涉及9项研究。研究的整体质量较高；研究全部分布在国外，如加拿大、美国和英国等；所有研究均采用Markov模型；健康结局均显示依奇珠单抗可以带来更多的质量调整生命年，但与甲氨蝶呤联合光疗、英夫利西单抗、乌司奴单抗及司库奇尤单抗治疗相比，增量成本-效用比（ICUR）在不同研究中存在差异。结论：依奇珠单抗对于治疗中重度斑块状银屑病具有一定的经济学优势，但缺乏国内研究数据，亟待开展适合中国人群的相关研究。 |
| ABSTRACT： | OBJECTIVE：To evaluate the drug economy of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. METHODS： Literatures were retrieved from PubMed ， Embase， The Cochrane Library ， CNKI and Wanfang database ， supplemented by manual search ，search time from the database establishment to Oct. 31st，2019，using Chinese and English search terms included “Ixekizumab”“Taltz”“Psoriasis”“Pharmacoeconomics”“Cost-benifit analysis ”“Cost-effectiveness analysis ” “Cost-utility analysis ”，etc. The literatures were screened according to inclusion and exclusion criteria. Relevant pharmacoeconomic studies about ixekizumab in the treatment of moderate-to-severe plaque psoriasis were collected ，and the study methods and pharmacoeconomic evaluation results were summarized. RESULTS ：A total of 8 literatures were included ，involving 9 studies. The overall quality of the studies was high. All the studies were distributed in foreign countries such as Canada ，the United States and the United Kingdom. All the studies adopted Markov model. The health outcomes showed that ixekizumab could bring more quality-adjusted life years. Compared with methotrexate combined with phototherapy ，infliximab，ustekinumab and secukinumab ， the incremental cost-utility ratio （ICUR）of ixekizumab was different in different studies. CONCLUSIONS ：Ixekizumab has certain economic advantages for the treatment of moderate-to-severe plaque psoriasis ，but there is still a lack of relevant research in China and it is urgent to carry out relevant research suitable for Chinese. |
| 期刊： | 2020年第31卷第07期 |
| 作者： | 刘国强，康朔 |
| AUTHORS： | LIU Guoqiang ，KANG Shuo |
| 关键字： | 依奇珠单抗；中重度斑块状银屑病；药物经济学；成本-效用分析 |
| KEYWORDS： | Ixekizumab；Moderate-to-severe plaque psoriasis ；Pharmacoeconomics；Cost-utility analysis |
| 阅读数： | 645 次 |
| 本月下载数： | 12 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
